Sarcoidosis
Sarcoidosis is not a single disease — it is a constellation. Optimal care requires evaluation across every organ system it can touch, not just the one that brought you in.
What we mean when we say Sarcoidosis.
Sarcoidosis is a systemic granulomatous disease of unknown etiology characterized by non-caseating granulomas in affected organs. Pulmonary involvement is most common, but cardiac, neurologic, ocular, dermatologic, hepatic, renal, and endocrine involvement are well-described and frequently under-recognized.
The clinical course ranges from asymptomatic and self-resolving to chronic and life-threatening. Cardiac sarcoidosis carries particular risk because it can present with arrhythmia or sudden death before recognition.
Diagnosis is clinical-radiologic-histologic, requiring exclusion of mimics and integration of findings across organ systems. Treatment ranges from observation to corticosteroids and steroid-sparing immunosuppression, with decisions that depend heavily on which organs are involved.
Approximately 1.2 million worldwide per Denning et al. Estimated 150,000–200,000 cases in the US. Higher prevalence and severity in Black populations.
Why Sarcoidosis gets missed.
Sarcoidosis is the multi-organ disease that almost no single specialist owns. Pulmonary sarcoidosis is recognized; cardiac, neurologic, ocular, and small-organ involvement frequently is not. The patient ends up with a pulmonologist who sees the lungs, an ophthalmologist who sees the eyes, a dermatologist who sees the skin, and no one synthesizing the whole.
- 01Non-pulmonary sarcoidosis is routinely missed. Cardiac sarcoidosis in particular can present with arrhythmia or sudden death before pulmonary disease is recognized — the screening for cardiac involvement is inconsistent even in patients with established pulmonary sarcoidosis.
- 02Treatment decisions vary widely. Some patients are placed on corticosteroids for stable, asymptomatic disease where observation would be appropriate; others have progressive disease and are under-treated. The risk-stratification literature is uneven across practice settings.
- 03Steroid-sparing immunosuppression — methotrexate, azathioprine, mycophenolate, and the biologics including infliximab — is under-utilized. Many patients with chronic sarcoidosis are kept on long-term corticosteroids past the point where transition to steroid-sparing therapy would be appropriate.
- 04The fatigue, cognitive symptoms, and small-fiber neuropathy that frequently accompany sarcoidosis are often dismissed or attributed to depression. Sarcoidosis-associated small fiber neuropathy is a recognized entity with specific implications, and is rarely worked up.
The Ternary Health approach to Sarcoidosis.
Map the full organ-involvement profile — pulmonary, cardiac, neurologic, ocular, dermatologic, hepatic, renal, endocrine — rather than evaluating each organ in isolation. The systemic picture changes treatment decisions.
Audit cardiac and neurologic screening specifically. These are the highest-risk organ involvements and the most frequently missed. Cardiac MRI, FDG-PET, neurologic imaging, and small-fiber workup are condition-appropriate and inconsistently applied.
Evaluate the treatment trajectory — corticosteroid duration, steroid-sparing transition, biologic considerations — against current evidence. Long-term steroid use without transition is a common pattern and is often inappropriate.
Address the fatigue, cognitive, and small-fiber symptom cluster explicitly. Sarcoidosis-associated SFN, fatigue syndromes, and cognitive symptoms are real and often unaddressed in standard care.
The Ternary Signal Library for Sarcoidosis.
Our Signal Library for Sarcoidosis codifies the specific patterns that matter — multi-organ imaging and biopsy findings, inflammatory and calcium markers, cardiac and neurologic surveillance, and the comorbid fatigue and small fiber patterns. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.
- —Chest CT and HRCT — pulmonary parenchymal and lymph node findings
- —Tissue biopsy site and granuloma confirmation
- —FDG-PET for active disease and occult involvement
- —MRI for cardiac, neurologic, and musculoskeletal involvement
- —Ophthalmologic examination — uveitis and posterior segment findings
- —ACE level — limited specificity, but pattern in context
- —Soluble IL-2 receptor where measured
- —Calcium and 1,25-vitamin D — hypercalcemia risk
- —Inflammatory markers — CRP, ESR trend
- —Liver function and renal function for organ involvement
- —Cardiac MRI for delayed enhancement and active inflammation
- —FDG-PET cardiac protocol where indicated
- —Holter and event monitoring for arrhythmia screening
- —Brain and spinal MRI for neurosarcoidosis
- —CSF studies where neurologic involvement suspected
- —Pulmonary function trend and DLCO trajectory
- —Pulmonary hypertension screening
- —Sarcoidosis-associated fatigue — distinct from active disease
- —Small fiber neuropathy screening
- —Cognitive dysfunction and mood pattern
How a Sarcoidosis case moves through our workflow.
Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.
What you receive.
- —A written case synthesis mapping organ involvement and treatment trajectory
- —Integration of imaging, biopsy, PFT, cardiac and neurologic workup into a single view
- —Cardiac and neurologic surveillance audit with specific testing recommendations
- —Treatment decision framework across corticosteroid, steroid-sparing immunosuppression, and biologic options
- —Fatigue, cognitive, and small fiber neuropathy assessment with management considerations
- —Specialist identification for sarcoidosis-experienced pulmonology, cardiac sarcoidosis centers, and indicated organ workups
- —A written action plan and follow-up support as you implement it
What a Precision Deep Dive provides for Sarcoidosis.
A Ternary Health Precision Deep Dive for sarcoidosis maps the full organ involvement profile, audits screening for cardiac, neurologic, and ocular involvement, synthesizes the immunosuppression evidence across first- and second-line agents, and evaluates fatigue, calcium, and endocrine complications frequently under-addressed in standard care.
See the published sample reports · read the Ternary Method
What we look for alongside Sarcoidosis.
Patients with Sarcoidosis frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.
- Cardiac arrhythmia
- Pulmonary hypertension
- Neurosarcoidosis
- Uveitis
- Hypercalcemia
- Small fiber neuropathy
What prospective Sarcoidosis clients ask most.
Three ways to engage Ternary on Sarcoidosis.
From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Sarcoidosis.
Free Brief
A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.
Generated instantly, no charge.
Get a free Brief→Launchpad
A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.
Delivered in 3–5 business days
Start a Launchpad→Precision Deep Dive
A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.
September 2026 cohort
Apply for a Deep Dive→See exactly what you receive.
A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Sarcoidosis — drawn from four research-validated patient profiles across four conditions.
Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.
Ready for clarity on your Sarcoidosis?
Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Sarcoidosis is generated instantly, no charge.